% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • rehdvm2004 rehdvm2004 Nov 26, 2012 7:22 AM Flag

    Change in INSM website pipeline menu . . .

    The INSM website has changed the drop down menu entitled "Pipeline."

    Longs should read the two descriptions therein:

    "Arikace" . . . and . . . "Other."

    These paragraphs lay to rest the wild speculations of the few remaining Pumpers.

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I would not be surprised if this is the work of one person.

      every insmed shareholder knows the drug is not part of inmseds future.

    • Actually the change was made yesterday (11/25/2012) around 5 PM. I was on the website reviewing INSM's BOD, headlines, SEC filings, etc. to see if the Lewis regime was going to update the website. I clicked on "Pipeline" and there were three items listed Arikace, Iplex and Other. I clicked on Iplex and there was nothing under the heading. Strange. So I clicked on Other and it said webpage unavailable. I was cooking dinner and came back around 5:30 PM to find Arikace and Other as the only two items listed under pipeline. I thought this was significant, particularly because of the wording about Iplex, Liposome Cisplatin and rhIGFBP-3. The quote about the outlicensing Iplex to Premacure was there which validated the recent headline on the Premacure website ( not months ago per the only responder). The other two outlicensed entities were described as in preclinical development. Again, Longs should read for themselves and make their own decision as to what has changed.

      Further, this change was posted twice yesterday and both posts were knocked off the MB. So let's see how Long this post remains.

      Sentiment: Hold

      • 1 Reply to rehdvm2004
      • When I typed "months ago", I meant months ago! Just because you noticed that only yesterday...well, not my problem. I am sure others had noted the change long ago, it did NOT occur yesterday, as you state. Yet another attempt on you part to weasel out of your inability to perform adequate/appropriate due diligence.

        As per your " not months ago per the only responder", no one else has responded that this change occurred yesterday, as you have attempted.

        You have no credibility and have long passed the zone of relevance.

    • That change was made months ago, it is about time you noticed it. I am NOT pumping, just stating the facts. You are quick to point or allege the "wild speculations" of others, what about yours? BTW, this is what the website states concerning IPLEX:

      "IPLEX is a complex of recombinant human IGF-1 and its binding protein IGFBP-3 (rhIGF-1/rhIGFBP-3) that has been studied as a treatment for several serious medical conditions. We have out-licensed rights to Premacure AB of Sweden to develop, manufacture and commercialize IGF-1, with its natural binding protein, IGFBP-3, at lower concentrations than IPLEX for the prevention and treatment of complications of preterm birth. Premacure is currently focusing on retinopathy of prematurity. We also plan to identify licensing partners for other IPLEX development programs."

      Also, thank you so very much for this, yet another attempt at your crack DD. I will wait with bated breath for your next announcement, lol!

      You have no credibility and have long passed the zone of relevance.

13.76-0.24(-1.71%)Oct 27 4:00 PMEDT